Clinical Trial Update: Phase I Oncovir Poly IC:LC and NY-ESO-1/gp100 [Phase 1]

View source ↗

Summary

Phase I trial update of a combination therapy using Poly IC:LC and NY-ESO-1/gp100 vaccine in melanoma. The study status is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• NY-ESO-1/gp100 peptide vaccine (NY-ESO-1/gp100 peptide vaccine)
• Poly IC:LC (polyinosinic-polycytidylic acid complexed with poly-L-lysine and carboxymethylcellulose (poly-ICLC))

Snippet

Sponsor: H. Lee Moffitt Cancer Center and Research Institute | Conditions: Melanoma | Phase 1 | Status: COMPLETED